Ausgabe 3/2017
Inhalt (16 Artikel)
Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery
Juhong Jiang, Yuanzhi Lu, Zhi Li, Liping Li, Daoli Niu, Wenwei Xu, Jing Liu, Lin Fu, Ziqing Zhou, Yingying Gu, Fen Xia
A truncated apoptin protein variant selectively kills cancer cells
Santiago Ruiz-Martínez, Jessica Castro, Maria Vilanova, Marta Bruix, Douglas V. Laurents, Marc Ribó, Antoni Benito
Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study
Naminatsu Takahara, Hiroyuki Isayama, Yousuke Nakai, Takashi Sasaki, Kazunaga Ishigaki, Kei Saito, Dai Akiyama, Rie Uchino, Suguru Mizuno, Hiroshi Yagioka, Hirofumi Kogure, Osamu Togawa, Saburo Matsubara, Yukiko Ito, Nobuo Toda, Minoru Tada, Kazuhiko Koike
State-dependent block of voltage-gated sodium channels by the casein-kinase 1 inhibitor IC261
Karl J. Föhr, Uwe Knippschild, Anna Herkommer, Michael Fauler, Christian Peifer, Michael Georgieff, Oliver Adolph
A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors
Christos E. Kyriakopoulos, Amy M. Braden, Jill M. Kolesar, Jens C. Eickhoff, Howard H. Bailey, Jennifer Heideman, Glenn Liu, Kari B. Wisinski
First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors
Andres Forero, Johanna C. Bendell, Prasanna Kumar, Linda Janisch, Michael Rosen, Qiang Wang, Catherine Copigneaux, Madhuri Desai, Giorgio Senaldi, Michael L. Maitland
A first-in-human Phase 1 study of epirubicin-conjugated polymer micelles (K-912/NC-6300) in patients with advanced or recurrent solid tumors
Hirofumi Mukai, Takahiro Kogawa, Nobuaki Matsubara, Yoichi Naito, Masaoki Sasaki, Ako Hosono
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors
Geoffrey I. Shapiro, Ulka N. Vaishampayan, Patricia LoRusso, Jeremy Barton, Steven Hua, Steven D. Reich, Ronald Shazer, Carrie T. Taylor, Dawei Xuan, Hossein Borghaei
First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors
S. Fu, H. Hirte, S. Welch, T. T. Ilenchuk, T. Lutes, C. Rice, N. Fields, A. Nemet, D. Dugourd, S. Piha-Paul, V. Subbiah, L. Liu, J. Gong, D. Hong, J. M. Stewart
Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study
Ravi Salgia, R. Waide Weaver, Michael McCleod, John R. Stille, S. Betty Yan, Stephanie Roberson, John Polzer, Amy Flynt, Eyas Raddad, Victoria L. Peek, Sameera R. Wijayawardana, Suzane L. Um, Steve Gross, Mark C. Connelly, Carrie Morano, Madeline Repollet, Renouard Sanders, Kurt Baeten, David D’Haese, David R. Spigel
A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer
M. Thomas, P. Sadjadian, J. Kollmeier, J. Lowe, P. Mattson, J. R. Trout, M. Gargano, M. L. Patchen, R. Walsh, M. Beliveau, J. F. Marier, N. Bose, K. Gorden, F. Schneller III
Current achievements and future perspectives of metronomic chemotherapy
Adriana Romiti, Rosa Falcone, Michela Roberto, Paolo Marchetti
Metabolic carbonyl reduction of anthracyclines — role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents
Kamil Piska, Paulina Koczurkiewicz, Adam Bucki, Katarzyna Wójcik-Pszczoła, Marcin Kołaczkowski, Elżbieta Pękala
Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?
Christos Fountzilas, Selena Stuart, Brian Hernandez, Elizabeth Bowhay-Carnes, Joel Michalek, John Sarantopoulos, Anand Karnad, Sukeshi Patel, Steven Weitman, Devalingam Mahalingam
Surveillance of protocol deviations in Japanese oncology registration trials: a single institute experience
Shinsuke Sasada, Nobuko Ushirozawa, Noriko Kobayashi, Yutaka Fujiwara, Kenji Tamura, Noboru Yamamoto
Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors
S. Fu, H. Hirte, S. Welch, T. T. Ilenchuk, T. Lutes, C. Rice, N. Fields, A. Nemet, D. Dugourd, S. Piha-Paul, V. Subbiah, L. Liu, J. Gong, D. Hong, J. M. Stewart